Baker Bros. Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Baker Bros. Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-117,638	Closed	-$10M	–	117
2017 Q4	$10M	Hold	117,638	–	–	0.09%	56
2017 Q3	$9.99M	Hold	117,638	–	–	0.08%	52
2017 Q2	$8.91M	Hold	117,638	–	–	0.08%	50
2017 Q1	$7.77M	Hold	117,638	–	–	0.06%	55
2016 Q4	$7.46M	Hold	117,638	–	–	0.07%	55
2016 Q3	$7.49M	Hold	117,638	–	–	0.07%	60
2016 Q2	$8.75M	Hold	117,638	–	–	0.09%	58
2016 Q1	$7.86M	Hold	117,638	–	–	0.08%	63
2015 Q4	$7.96M	Hold	117,638	–	–	0.07%	66
2015 Q3	$6.29M	Hold	117,638	–	–	0.06%	73
2015 Q2	$7.41M	Hold	117,638	–	–	0.07%	69
2015 Q1	$5.66M	Sell	117,638 -22	-0%	-$843	0.05%	73
2014 Q4	$3.91M	Hold	117,660	–	–	0.04%	79
2014 Q3	$3.45M	Hold	117,660	–	–	0.04%	75
2014 Q2	$4.57M	Hold	117,660	–	–	0.06%	73
2014 Q1	$4.94M	Hold	117,660	–	–	0.06%	70
2013 Q4	$3.86M	Hold	117,660	–	–	0.05%	71
2013 Q3	$3.18M	Hold	117,660	–	–	0.05%	64
2013 Q2	$2.75M	Buy	+117,660	New	+$2.12M	0.05%	59

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Baker Bros. Advisors's LGND Position: Q1 2018 in Review

Baker Bros. Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2018, closing a stake of 117,638 shares — an estimated $10M sold.

Baker Bros. Advisors first reported a position in LGND in Q2 2013 and held it in 19 quarters. The position peaked at $10M in Q4 2017. 326 funds tracked by Wall St. Rank hold LGND as of Q1 2018.

Baker Bros. Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Baker Bros. Advisors sold 117,638 Ligand Pharmaceuticals shares in Q1 2018, an estimated $10M.
Baker Bros. Advisors first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 19 quarters.
Baker Bros. Advisors's Ligand Pharmaceuticals position peaked at $10M in Q4 2017.
326 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2018.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.